Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,totalCurrentAssets,netReceivables,accountsPayable,otherCurrentAssets,longTermInvestments,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,changeToNetincome,otherCashflowsFromFinancingActivities,investments,totalCashflowsFromInvestingActivities,netBorrowings,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,postMarketChangePercent,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,postMarketTime,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GBS,15899411.0,12382100,2156316,,-3142667,-53995,-3127813,1013389,34290,-3135415,-3135415,,-18561,,,,0,34290,3169705,0,-7252,,-3142667,-3127813,38440097.0,1577262.0,15899411.0,866667.0,17452678.0,118813.0,-22016804.0,18128.0,-642695.0,866667.0,14261622.0,1559134.0,-642695.0,16586011.0,97168.0,1392765.0,,,339180.0,498100.0,-3102327.0,498100.0,-5616238.0,45097.0,-6159435.0,-268475.0,,,,,,15026877.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,GBS Inc.,False,False,NGM,-2.9177692,3.77,1630526402,0.53,4.77,4.87,3.6,27344948,POST,0,4,3.66,-0.109999895,16.358025,3.6 - 4.87,3.24,3.64,3.7,18,9,finmb_578948353,GBS Inc.,1630533046,NasdaqGM,USD,814354,181816,1.329,0.544449,2.441 - 14.24,-10.469999,-0.7352528,2.441,14.24,3.2251666,0.5448334,0.16893187,4.4010797,-0.6310797,-0.14339201,46680516,15,America/New_York,EDT,-14400000,,,,14.24,2.441,3.2252,4.4011,814.35k,181.82k,12.38M,,9.58M,,,88.14k,0.29,2.30%,0.71%,76.13k,,,,,,0.00%,,,2000:1,"Apr 09, 2017","Jun 29, 2020","Mar 30, 2021",0.00%,"-1,078.00%",-30.70%,-133.02%,441.75k,0.05,,188.74k,,-6.61M,,,14.26M,1.15,,,10.64,,-9.42M,-4.34M,Value,10017,Healthcare,7,"GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.",New York,646 828 8258,NY,1609372800,United States,http://www.gbs.inc,86400,708 3rd Avenue,Medical Devices,6th Floor
t-1,GBS,18791156.0,12382100,341820,,-1990389,-39141,-1983964,671450,283037,-730233,-730233,,-986860,,,,0,283037,1013270,0,-1260156,,-1990389,-1983964,37956585.0,1184393.0,18791156.0,,19966408.0,104225.0,-18888991.0,17947.0,-380663.0,,19877860.0,1166446.0,-380663.0,19966408.0,86952.0,1027170.0,,,362035.0,19610073.0,-22244.0,21610213.0,18883674.0,-14949.0,-711450.0,937128.0,-2000140.0,,,,,18799962.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,GBS Inc.,False,False,NGM,-2.9177692,3.77,1630526402,0.53,4.77,4.87,3.6,27344948,POST,0,4,3.66,-0.109999895,16.358025,3.6 - 4.87,3.24,3.64,3.7,18,9,finmb_578948353,GBS Inc.,1630533046,NasdaqGM,USD,814354,181816,1.329,0.544449,2.441 - 14.24,-10.469999,-0.7352528,2.441,14.24,3.2251666,0.5448334,0.16893187,4.4010797,-0.6310797,-0.14339201,46680516,15,America/New_York,EDT,-14400000,,,,14.24,2.441,3.2252,4.4011,814.35k,181.82k,12.38M,,9.58M,,,88.14k,0.29,2.30%,0.71%,76.13k,,,,,,0.00%,,,2000:1,"Apr 09, 2017","Jun 29, 2020","Mar 30, 2021",0.00%,"-1,078.00%",-30.70%,-133.02%,441.75k,0.05,,188.74k,,-6.61M,,,14.26M,1.15,,,10.64,,-9.42M,-4.34M,Value,10017,Healthcare,7,"GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.",New York,646 828 8258,NY,1609372800,United States,http://www.gbs.inc,86400,708 3rd Avenue,Medical Devices,6th Floor
t-2,GBS,-23638277.0,12382100,30938,,-1072510,-32716,-1068105,511733,55427,-492109,-492109,4865.0,-85828,,,,0,55427,547536,0,-580401,,-1072510,-1068105,,5953722.0,-23638277.0,,2906156.0,2850001.0,-16905027.0,15605.0,-9583251.0,,994186.0,5938117.0,-9583251.0,2906156.0,19435.0,676361.0,1863613.0,,-1752351.0,3294745.0,705.0,21610213.0,566913.0,14949.0,-2742781.0,76970.0,-2000140.0,,,,,-3031961.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,GBS Inc.,False,False,NGM,-2.9177692,3.77,1630526402,0.53,4.77,4.87,3.6,27344948,POST,0,4,3.66,-0.109999895,16.358025,3.6 - 4.87,3.24,3.64,3.7,18,9,finmb_578948353,GBS Inc.,1630533046,NasdaqGM,USD,814354,181816,1.329,0.544449,2.441 - 14.24,-10.469999,-0.7352528,2.441,14.24,3.2251666,0.5448334,0.16893187,4.4010797,-0.6310797,-0.14339201,46680516,15,America/New_York,EDT,-14400000,,,,14.24,2.441,3.2252,4.4011,814.35k,181.82k,12.38M,,9.58M,,,88.14k,0.29,2.30%,0.71%,76.13k,,,,,,0.00%,,,2000:1,"Apr 09, 2017","Jun 29, 2020","Mar 30, 2021",0.00%,"-1,078.00%",-30.70%,-133.02%,441.75k,0.05,,188.74k,,-6.61M,,,14.26M,1.15,,,10.64,,-9.42M,-4.34M,Value,10017,Healthcare,7,"GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.",New York,646 828 8258,NY,1609372800,United States,http://www.gbs.inc,86400,708 3rd Avenue,Medical Devices,6th Floor
t-3,GBS,-22515199.0,12382100,47183,,-457016,-28311,-450052,443979,69000,-422162,-422162,4865.0,-76784,,,,0,69000,491162,0,-34854,,-457016,-450052,,7690468.0,-22515199.0,,2475640.0,2850001.0,-15832517.0,,-9532683.0,,427273.0,7690468.0,-9532683.0,2339948.0,19593.0,2252869.0,1863613.0,135692.0,-475910.0,201514.0,705.0,21610213.0,409202.0,26713.0,194975.0,1282854.0,-2000140.0,-14000.0,-14000.0,-150986.0,-161917.0,-5350520.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,GBS Inc.,False,False,NGM,-2.9177692,3.77,1630526402,0.53,4.77,4.87,3.6,27344948,POST,0,4,3.66,-0.109999895,16.358025,3.6 - 4.87,3.24,3.64,3.7,18,9,finmb_578948353,GBS Inc.,1630533046,NasdaqGM,USD,814354,181816,1.329,0.544449,2.441 - 14.24,-10.469999,-0.7352528,2.441,14.24,3.2251666,0.5448334,0.16893187,4.4010797,-0.6310797,-0.14339201,46680516,15,America/New_York,EDT,-14400000,,,,14.24,2.441,3.2252,4.4011,814.35k,181.82k,12.38M,,9.58M,,,88.14k,0.29,2.30%,0.71%,76.13k,,,,,,0.00%,,,2000:1,"Apr 09, 2017","Jun 29, 2020","Mar 30, 2021",0.00%,"-1,078.00%",-30.70%,-133.02%,441.75k,0.05,,188.74k,,-6.61M,,,14.26M,1.15,,,10.64,,-9.42M,-4.34M,Value,10017,Healthcare,7,"GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.",New York,646 828 8258,NY,1609372800,United States,http://www.gbs.inc,86400,708 3rd Avenue,Medical Devices,6th Floor
